glp-1 gip lilly LY3437943, a novel triple glucagon, GIP, and receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism GLP-1 Pipeline Update: May 2026

Linda, 65, needle phobic : Linda strongly preferred avoiding injections despite understanding they might be more effective

This structural advantage gives tesamorelin a longer duration of action and a more potent GH response

Lawsuits filed against Eli Lilly are being consolidated into the same multidistrict litigation alongside claims against Novo Nordisk, as many plaintiffs allege similar injuries and legal issues

Maximizing the value of GLP-1RAs and next-generation pleiotropic drugs will demand effective navigation of data management and analysis, deals and licensing, regulatory exclusivity, and strategic patent prosecution

GLP-1 analogues are powerful metabolic tools, but they demand strict medical oversight

For same-day availability, please DM us on Instagram @bianca_clinic_tokyo